12.48
Jade Biosciences Inc stock is traded at $12.48, with a volume of 235.23K.
It is up +24.80% in the last 24 hours and up +0.00% over the past month.
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
See More
Previous Close:
$10.00
Open:
$10.18
24h Volume:
235.23K
Relative Volume:
34.07
Market Cap:
$533.36M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
Jade Biosciences Inc Stock (JBIO) Company Profile
Name
Jade Biosciences Inc
Sector
Industry
Phone
617-443-2400
Address
930 WINTER STREET, WALTHAM
Compare JBIO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
JBIO
Jade Biosciences Inc
|
12.48 | 533.36M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-18-24 | Downgrade | Evercore ISI | Outperform → In-line |
Jun-18-24 | Downgrade | TD Cowen | Buy → Hold |
Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
Jun-17-24 | Downgrade | Guggenheim | Buy → Neutral |
Jun-17-24 | Downgrade | Wedbush | Outperform → Neutral |
Mar-25-24 | Resumed | Jefferies | Buy |
Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
Mar-01-23 | Initiated | Guggenheim | Buy |
Dec-06-22 | Upgrade | BTIG Research | Neutral → Buy |
Sep-19-22 | Resumed | Wedbush | Outperform |
Aug-16-22 | Downgrade | BTIG Research | Buy → Neutral |
Feb-11-22 | Initiated | BTIG Research | Buy |
Jul-26-21 | Initiated | Cowen | Outperform |
Jul-26-21 | Initiated | Evercore ISI | Outperform |
Jul-26-21 | Initiated | Jefferies | Buy |
Jul-26-21 | Initiated | Wedbush | Outperform |
View All
Jade Biosciences Inc Stock (JBIO) Financials Data
There is no financial data for Jade Biosciences Inc (JBIO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):